X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Kindeva will perform commercial manufacturing process development and manufacture clinical supplies for Aversa Fentanyl, which combines Nutriband's AVERSA™ abuse-deterrent transdermal technology with Kindeva's FDA-approved transdermal fentanyl patch system.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa Fentanyl
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nutriband
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2024
Details:
AVERSA™ (fentanyl) combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch system.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Aversa
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Nutriband
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee.
Lead Product(s): Diclofenac Epolamine
Therapeutic Area: Musculoskeletal Product Name: Epoladerm
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Virpax Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
Breyna (Budesonide and Formoterol Fumarate Dihydrate), first approved generic version of AstraZeneca's Symbicort, a drug-device combination product, is indicated for certain patients with asthma or COPD and will be available in 160 /4.5 and 80/4.5 mcg dosage strengths.
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Breyna
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Viatris
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
Albuterol sulfate is used to treat or prevent bronchospasm in patients four years and older with reversible obstructive airway disease, such as asthma, and to prevent exercise-induced bronchospasm.
Lead Product(s): Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Proventil HFA
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 16, 2021
Details:
The U.S. Food and Drug Administration (FDA) granted tentative approval of budesonide/formoterol fumarate dihydrate products, the first generic version of Symbicort based on an Abbreviated New Drug Application (ANDA).
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Viatris
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
Under the agreement, Kindeva will develop novel formulations of BOL Pharma’s cannabinoid based drug products delivered by Kindeva’s metered-dose inhaler (MDI) technology.
Lead Product(s): BOL-DP-o-04
Therapeutic Area: Neurology Product Name: BOL-DP-o-04
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BOL Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
